Literature DB >> 7075107

Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin.

C Richer, M Mathieu, H Bah, C Thuillez, P Duroux, J F Giudicelli.   

Abstract

The kinetics and the effects on the ventilatory function peak expiratory flow rate (PEFR) of a single 600-mg oral dose of theophylline were investigated in 46 adult patients with bronchial asthma (BA) and in 16 adult patients with chronic airflow obstruction (CAO). In the former, theophylline induced an early and potent bronchodilatation (60% rise in PEFR), the kinetics of which correlated with plasma concentration. Theophylline was also effective in patients with CAO, but the magnitude of its bronchodilator effect was less than in those with BA: this was despite plasma concentrations of much the same order. In adult patients with BA (but not with CAO) theophylline plasma levels and bioavailability are higher after simultaneous erythromycin dosing.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075107     DOI: 10.1038/clpt.1982.81

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 2.  Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.

Authors:  D M Newnham
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Sustained release theophylline preparations. Practical recommendations for prescribing and therapeutic drug monitoring.

Authors:  A Glynn-Barnhart; M Hill; S J Szefler
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 4.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 5.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 6.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

7.  Spiramycin has no effect on serum theophylline in asthmatic patients.

Authors:  D Debruyne; A Jehan; M C Bigot; B Lechevalier; J N Prevost; M Moulin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

9.  Sustained serum theophylline concentrations during chronic twice daily administration of a slow release preparation.

Authors:  S H Jackson; J M Wright
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.